Nipocalimab
High EvidenceNipocalimab (brand name Imaavy, development code M281) is a fully human, aglycosylated, 'effectorless' IgG1 monoclonal antibody that blocks the neonatal Fc receptor (FcRn), developed by Johnson & Johnson (Janssen). Like efgartigimod it lowers circulating immunoglobulin G (IgG) - including the pathogenic autoantibodies that drive many autoimmune diseases - by occupying FcRn and preventing it from recycling IgG back into the blood, so unrescued IgG is routed to the lysosome and degraded, typically cutting total IgG by roughly 65-75% while sparing IgM, IgA, complement, and albumin. Unlike efgartigimod's engineered Fc fragment, nipocalimab is a full-length monoclonal antibody engineered to be aglycosylated and effectorless (it does not trigger ADCC or complement-dependent cytotoxicity), and it is dosed as a maintenance intravenous infusion for continuous IgG suppression rather than in short cycles. The FDA approved Imaavy on April 30, 2025 for generalized myasthenia gravis (gMG) in anti-AChR-antibody-positive and anti-MuSK-antibody-positive patients aged 12 and older - making it the first FcRn blocker approved for adolescents and the first to explicitly cover MuSK-positive disease - on the strength of the Phase 3 Vivacity-MG3 trial. It has since generated positive data across a striking breadth of IgG-mediated conditions: Sjogren's disease (Phase 2 DAHLIAS), rheumatoid arthritis, warm autoimmune hemolytic anemia (wAIHA), and - uniquely among FcRn blockers - maternal-fetal alloimmune disease, where it is being developed to treat hemolytic disease of the fetus and newborn (HDFN) by crossing the placenta to protect the fetus. In April 2026 the FDA granted Priority Review to nipocalimab for wAIHA, positioning it as a potential first approved therapy for that condition.
What It Is
Nipocalimab is the second FcRn blocker to reach the U.S. market and, in many ways, the mechanism's broadest bet. It shares efgartigimod's core idea - jam the receptor that recycles IgG so the body's own antibodies, including the harmful ones, get degraded instead of rescued - but arrives at it from a different molecular design and a much wider clinical ambition. Where efgartigimod is an isolated, ABDEG-modified Fc fragment dosed in cycles, nipocalimab is a full-length, fully human IgG1 monoclonal antibody that Johnson & Johnson engineered to be aglycosylated (its Fc sugar removed) and therefore 'effectorless' - it binds FcRn with high affinity but does not recruit immune effector functions like antibody-dependent cellular cytotoxicity or complement activation, so its only job is to occupy FcRn. By saturating FcRn, nipocalimab blocks the salvage pathway that normally rescues IgG from lysosomal destruction and returns it to circulation; unrescued IgG is degraded, dropping total IgG by roughly 65-75% with continued dosing while leaving IgM, IgA, complement, and albumin essentially untouched. It is given as a maintenance intravenous infusion aimed at sustained IgG lowering, a different rhythm from efgartigimod's cyclic 'reduce and recover' approach. The FDA approved Imaavy (nipocalimab-aahu) on April 30, 2025 for generalized myasthenia gravis, and the label is notable for its breadth: it covers both anti-acetylcholine-receptor (AChR) and anti-MuSK antibody-positive patients and reaches down to age 12, making nipocalimab the first FcRn blocker approved for adolescents and the first to explicitly include MuSK-positive gMG. Approval rested on Vivacity-MG3, a Phase 3 placebo-controlled trial in which nipocalimab plus standard of care produced a statistically significant, sustained reduction in the MG-ADL daily-living score over weeks 22 to 24 versus placebo plus standard of care - a design that emphasized durable disease control rather than a single time point. What sets nipocalimab apart is how far Johnson & Johnson has pushed the FcRn mechanism beyond neuromuscular disease. In the Phase 2 DAHLIAS trial in moderate-to-severe Sjogren's disease, nipocalimab met its primary endpoint with a significant improvement in the ClinESSDAI disease-activity scale at 24 weeks, earning FDA Breakthrough Therapy (2024) and Fast Track (2025) designations and a publication in The Lancet; it has also shown activity in rheumatoid arthritis and, in January 2026, received Fast Track designation for systemic lupus erythematosus. Most distinctively, nipocalimab is the FcRn blocker being developed in pregnancy: because IgG crosses the placenta via FcRn, maternal alloantibodies can attack fetal red cells or platelets, and nipocalimab is designed to block that transfer. In the Phase 2 UNITY study in pregnancies at high risk of early-onset severe hemolytic disease of the fetus and newborn (HDFN), 54% of treated alloimmunized women achieved a live birth at or after 32 weeks' gestation without needing an intrauterine transfusion - a result published in the New England Journal of Medicine and now being confirmed in the Phase 3 AZALEA trial, with a parallel program in fetal and neonatal alloimmune thrombocytopenia (FNAIT). In April 2026 the FDA granted Priority Review to nipocalimab for warm autoimmune hemolytic anemia (wAIHA), based on the ENERGY trial, which would make it a potential first approved therapy for that disease. Taken together, nipocalimab is less a single-indication drug than an attempt to turn FcRn blockade into a platform spanning neurology, rheumatology, hematology, and maternal-fetal medicine, and it is the principal benchmark against which efgartigimod and the newer FcRn antagonists rozanolixizumab and batoclimab are measured.
Regulatory Status
Nipocalimab-aahu is an FDA-approved prescription biologic marketed by Johnson & Johnson (Janssen) as Imaavy. It is not a dietary supplement, a compounded product, or a research chemical, and it must be prescribed and administered under medical supervision as an intravenous infusion; any 'nipocalimab' or 'M281' offered by a research-chemical vendor is unverified and should not be used. Approved U.S. indication: generalized myasthenia gravis in anti-AChR-antibody-positive and anti-MuSK-antibody-positive patients aged 12 years and older (approved April 30, 2025). Under FDA Priority Review for warm autoimmune hemolytic anemia (wAIHA) as of April 2026. Investigational for Sjogren's disease, rheumatoid arthritis, systemic lupus erythematosus, hemolytic disease of the fetus and newborn (HDFN), and fetal/neonatal alloimmune thrombocytopenia (FNAIT). Identifiers: CAS 2211985-36-1; DrugBank DB16257. It is a fully human, aglycosylated (effectorless) IgG1 monoclonal antibody (~146 kDa), not a small synthetic peptide.
Why Researchers Study It
Nipocalimab matters to researchers as the second FcRn blocker to reach the market and the one testing how far the mechanism can stretch. It validates FcRn blockade with a fundamentally different molecule from efgartigimod - a full-length, aglycosylated, effectorless IgG1 monoclonal antibody dosed for continuous IgG suppression rather than an Fc fragment dosed in cycles - which makes the two a natural head-to-head study in antibody engineering: fragment versus whole antibody, cyclic versus maintenance dosing, and how each shapes the depth, durability, and safety of IgG lowering. It is also the FcRn blocker with the broadest clinical footprint, generating controlled data across generalized myasthenia gravis, Sjogren's disease, rheumatoid arthritis, lupus, warm autoimmune hemolytic anemia, and - uniquely - maternal-fetal alloimmune disease, which lets researchers ask which IgG-driven diseases truly respond to lowering the antibody pool. Its use in pregnancy is scientifically distinctive: because FcRn is the transporter that carries maternal IgG across the placenta, nipocalimab is a direct probe of placental antibody transfer and a potential non-transfusion treatment for hemolytic disease of the fetus and newborn, an application no small-molecule or complement drug can reach the same way. Finally, its approval spanning adolescents and MuSK-positive disease, and its aglycosylated effectorless design, make it a reference point for how monoclonal-antibody format choices translate into label breadth and safety in the FcRn class.
Proposed Mechanisms
- Fully human, aglycosylated IgG1 monoclonal antibody that binds the neonatal Fc receptor (FcRn) with high affinity - a full-length antibody rather than the isolated Fc fragment used by efgartigimod, and not a small synthetic peptide
- Engineered to be 'effectorless': removing the Fc glycan (aglycosylation) prevents it from triggering antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity, so its only pharmacologic action is to occupy FcRn
- By saturating FcRn, it blocks FcRn-mediated recycling of endogenous IgG; IgG that would normally be rescued from the endosome and returned to the blood is instead routed to the lysosome and degraded, lowering total circulating IgG by roughly 65-75% with continued dosing
- Selectively reduces all IgG subclasses - including pathogenic autoantibodies driving diseases like myasthenia gravis, Sjogren's disease, and hemolytic anemia - without lowering IgM, IgA, complement, or albumin, distinguishing it from broad immunosuppression, plasma exchange, and IVIg
- Dosed as a maintenance intravenous infusion for sustained IgG suppression, a different regimen from efgartigimod's short cyclic 'reduce and recover' dosing
- In pregnancy, blocks the same FcRn that transports maternal IgG across the placenta, so it can reduce transfer of maternal alloantibodies to the fetus - the basis for its development in hemolytic disease of the fetus and newborn (HDFN) and fetal/neonatal alloimmune thrombocytopenia (FNAIT)
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Phase 3 (Vivacity-MG3, NCT04951622) - randomized, double-blind, placebo-controlled | Adults with generalized myasthenia gravis (anti-AChR and anti-MuSK antibody-positive); intravenous nipocalimab plus standard of care versus placebo plus standard of care over 24 weeks | Met the primary endpoint with a statistically significant, sustained reduction in MG-ADL score over weeks 22-24 versus placebo. Basis for the April 30, 2025 FDA approval of Imaavy for gMG in antibody-positive patients aged 12 and older - the first FcRn blocker approved for adolescents and for MuSK-positive disease. Published in The Lancet Neurology, 2025 | Source |
| Phase 2 (DAHLIAS, NCT04968912) - randomized, double-blind, placebo-controlled | Anti-Ro/SSA-seropositive adults with moderate-to-severe Sjogren's disease; intravenous nipocalimab (including 15 mg/kg every 2 weeks) versus placebo over 24 weeks | Met the primary endpoint with a statistically significant improvement in the ClinESSDAI disease-activity scale at week 24, plus patient-reported gains in dryness and pain. Supported FDA Breakthrough Therapy (November 2024) and Fast Track (March 2025) designations. Published in The Lancet, 2025 | Source |
| Phase 2 (UNITY, NCT03842189) - open-label, single-arm | Pregnant individuals at high risk of early-onset severe hemolytic disease of the fetus and newborn (HDFN); weekly intravenous nipocalimab from ~14 to 35 weeks' gestation | 54% of treated alloimmunized women achieved a live birth at or after 32 weeks' gestation without any intrauterine transfusion during pregnancy - a marked improvement over the expected outcome in this high-risk group, and the first demonstration that an FcRn blocker can protect the fetus by reducing transplacental IgG transfer. Published in the New England Journal of Medicine, 2024; confirmatory Phase 3 AZALEA underway | Source |
| Phase 2/3 (ENERGY) - randomized, double-blind, placebo-controlled | Adults with warm autoimmune hemolytic anemia (wAIHA); intravenous nipocalimab versus placebo, evaluating durable hemoglobin response | Investigational: FcRn blockade lowers the anti-red-cell IgG that drives hemolysis in wAIHA. Data supported an FDA Priority Review granted April 27, 2026 for a potential first approved wAIHA therapy; wAIHA is not yet an approved indication | Source |
Commonly Discussed Benefits
Researching Nipocalimab? Track it, set reminders, and keep notes in the free app.
Safety & Cautions
- Nipocalimab is a prescription biologic that must be administered under medical supervision as an intravenous infusion (Imaavy); it is not a supplement or self-sourced research chemical, and any product sold as 'nipocalimab' or 'M281' outside a pharmacy or clinical trial is unverified and unsafe
- By design it lowers total IgG by roughly 65-75%, which can increase susceptibility to infections, particularly upper respiratory and urinary tract infections; infections, headache, and infusion-related reactions were among the most common adverse events in trials
- The long-term consequences of sustained IgG reduction - including cumulative infection risk and response to vaccines - are still being characterized, and live vaccines are generally avoided during treatment
- In pregnancy, sustained maternal IgG lowering also reduces protective maternal antibody transferred to the infant; the balance of fetal benefit (in HDFN/FNAIT) against altered neonatal immunity is still being studied, and use in pregnancy is investigational
- It selectively reduces IgG but does not address non-IgG disease mechanisms; it is not effective for conditions driven by IgM, T cells, or complement independent of IgG, and is not a traditional immunosuppressant
- Only generalized myasthenia gravis (antibody-positive, age 12+) is an approved indication; use in Sjogren's disease, rheumatoid arthritis, lupus, warm autoimmune hemolytic anemia, HDFN, and FNAIT remains investigational and unproven, and it has no established role in performance enhancement, anti-aging, or general wellness
Comparisons
See how Nipocalimab compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Johnson & Johnson receives FDA approval for IMAAVY (nipocalimab-aahu), a new FcRn blocker for generalized myasthenia gravis (gMG) - Johnson & Johnson, April 2025 PubMed
- [2] FDA Approves FcRn Blocker Nipocalimab for Broad Forms of Generalized Myasthenia Gravis (Vivacity-MG3) - NeurologyLive PubMed
- [3] Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjogren's disease (DAHLIAS) - The Lancet, 2025 PubMed
- [4] Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn (UNITY) - New England Journal of Medicine, 2024 PubMed
- [5] FDA grants Priority Review for IMAAVY (nipocalimab-aahu) as potential first approved treatment for warm autoimmune hemolytic anemia (wAIHA) - Johnson & Johnson, April 2026 PubMed
- [6] Nipocalimab (M281): identifiers, mechanism of action, indications - DrugBank DB16257 PubMed
- [7] Nipocalimab - Wikipedia (overview, aglycosylated effectorless anti-FcRn IgG1, CAS 2211985-36-1) PubMed
Keep researching in the app
- Log Nipocalimab to your private tracker
- Set a dosing reminder
- Compare it side-by-side with your stack
Related Peptides
Zilucoplan
High EvidenceA self-administered, once-daily subcutaneous macrocyclic peptide that inhibits complement component 5 (C5), FDA- and EMA-approved for anti-AChR-positive generalized myasthenia gravis.
Efzofitimod
Medium EvidenceA first-in-class, intravenous immunomodulatory fusion peptide derived from histidyl-tRNA synthetase that selectively binds neuropilin-2 (NRP2) to dampen inflammation in the lung; in Phase 3 development for pulmonary sarcoidosis, an interstitial lung disease.
Pegcetacoplan
High EvidenceA PEGylated cyclic-peptide inhibitor of complement component 3 (C3) built from two compstatin (Cp05) peptide domains bridged by a 40-kDa PEG chain; marketed as Empaveli/Aspaveli (subcutaneous, for paroxysmal nocturnal hemoglobinuria and, since July 2025, C3 glomerulopathy and primary IC-MPGN) and Syfovre (intravitreal, for geographic atrophy in age-related macular degeneration). It is one of the few complement-targeting therapeutic peptides to reach the market.
Sotatercept
High EvidenceSotatercept (Winrevair, sotatercept-csrk) is Merck's first-in-class activin signaling inhibitor - a recombinant ActRIIA-Fc fusion protein that acts as a ligand trap for activin A, activin B, GDF-8 (myostatin) and GDF-11. It is FDA-approved for adults with pulmonary arterial hypertension (PAH), where it improved 6-minute walk distance by 40.8 meters in the Phase 3 STELLAR trial and, in the Phase 3 ZENITH trial in high-risk patients, cut the composite risk of death, lung transplantation and PAH hospitalization by 76%. An expanded U.S. label reflecting ZENITH was approved on October 27, 2025.
Efgartigimod
High EvidenceEfgartigimod (efgartigimod alfa, brand names Vyvgart intravenous and Vyvgart Hytrulo subcutaneous) is a first-in-class antagonist of the neonatal Fc receptor (FcRn) developed by argenx as ARGX-113. It is not a small synthetic peptide but an engineered fragment of the human immunoglobulin G1 (IgG1) antibody - specifically the Fc portion that normally binds FcRn - modified with argenx's ABDEG technology to bind FcRn with much higher affinity than natural IgG at both neutral and acidic pH. FcRn is the salvage receptor that rescues circulating IgG from lysosomal degradation and recycles it back into the blood, giving antibodies their long half-life. By outcompeting endogenous IgG for FcRn, efgartigimod blocks that recycling and drives rapid clearance of IgG - including the pathogenic autoantibodies that cause many autoimmune diseases - typically lowering total IgG by roughly 60-70% within weeks, without reducing IgM, IgA, or albumin. It was the first FcRn blocker ever approved: FDA-approved in December 2021 (Vyvgart IV) for acetylcholine-receptor-antibody-positive generalized myasthenia gravis (gMG) on the strength of the Phase 3 ADAPT trial, followed by a subcutaneous co-formulation with recombinant hyaluronidase (Vyvgart Hytrulo) for gMG in 2023 and for chronic inflammatory demyelinating polyneuropathy (CIDP) in 2024. In May 2026 the FDA expanded the gMG label to all serotypes - including AChR-antibody-negative (seronegative) patients - based on the Phase 3 ADAPT SERON trial, making efgartigimod the first and only therapy approved across every gMG antibody subtype. It is being studied in a broad set of other IgG-driven autoimmune diseases, including primary immune thrombocytopenia, myositis, Sjogren's disease, bullous pemphigoid, and lupus nephritis.
Rozanolixizumab
High EvidenceRozanolixizumab (brand name Rystiggo, development code UCB7665) is a humanized IgG4 monoclonal antibody that blocks the neonatal Fc receptor (FcRn), developed by UCB. Like efgartigimod and nipocalimab it lowers circulating immunoglobulin G (IgG) - including the pathogenic autoantibodies that drive many autoimmune diseases - by binding FcRn and preventing it from recycling IgG back into the blood, so unrescued IgG is routed to the lysosome and degraded, typically cutting total IgG by roughly 70-80% while sparing IgM, IgA, complement, and albumin. Unlike efgartigimod's engineered Fc fragment, rozanolixizumab is a full-length humanized antibody, and unlike nipocalimab's intravenous infusion it is given as a rapid subcutaneous infusion (including via an on-body delivery device), typically in weekly cycles that are repeated based on clinical response rather than continuously. The FDA approved Rystiggo on June 27, 2023 for generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine-receptor (AChR) antibody-positive or anti-muscle-specific-tyrosine-kinase (MuSK) antibody-positive - making it the first therapy ever approved to treat both of those gMG subtypes - on the strength of the Phase 3 MycarinG trial. It has since been studied across other IgG-mediated diseases, including chronic inflammatory demyelinating polyneuropathy (CIDP), where it did not show meaningful benefit and was not advanced to Phase 3, and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), primary immune thrombocytopenia (ITP), and other autoantibody conditions where development continues. The European Medicines Agency approved rozanolixizumab in January 2024 and the UK MHRA in March 2024.
Batoclimab
High EvidenceBatoclimab (development codes IMVT-1401, RVT-1401, HBM9161, HL161) is an investigational, fully human IgG1 monoclonal antibody that blocks the neonatal Fc receptor (FcRn), developed by Immunovant/Roivant (U.S. and Canada) and Harbour BioMed (Greater China) under license from HanAll Biopharma. It is not a small synthetic peptide but a full-length antibody given as a low-volume subcutaneous injection that patients can self-administer at home. Like the approved FcRn blockers efgartigimod, nipocalimab and rozanolixizumab, it lowers circulating IgG - including pathogenic autoantibodies - but it is best known for two things the others are not: it is the FcRn blocker that generated positive Phase 3 myasthenia gravis data yet was deliberately NOT filed for U.S. approval, and it is the one whose FcRn-mediated albumin recycling blockade produces a distinctive on-target signal of lowered serum albumin and raised LDL cholesterol - the exact liability that drove its makers to a re-engineered successor, IMVT-1402.
IMVT-1402
Medium EvidenceIMVT-1402 (international nonproprietary name imeroprubart; originally HL161ANS) is Immunovant/Roivant's investigational, next-generation, fully human IgG1 monoclonal antibody that blocks the neonatal Fc receptor (FcRn). It is a re-engineered successor to batoclimab, built to keep batoclimab's deep IgG-lowering while removing that molecule's defining liability: because FcRn recycles serum albumin as well as IgG, first-generation FcRn blockers reproducibly lowered albumin and raised LDL cholesterol, and IMVT-1402 was specifically designed to spare albumin and lipids. Like the approved FcRn blockers efgartigimod, nipocalimab and rozanolixizumab it lowers circulating IgG - including pathogenic autoantibodies - but it is distinguished by two things: a low-volume subcutaneous autoinjector for at-home self-administration, and Phase 1 data showing 60-80% IgG reduction with no albumin drop and no LDL rise. It is now Immunovant's lead pipeline asset, advancing across roughly six autoimmune indications with potentially registrational Graves' disease and myasthenia gravis readouts expected in 2027.